Skip to content
‹ Back to IndustriesHealthcare

Hurricane Maria Continues to Wreak Havoc on the Medical Industry

Though it has been nearly four months since Hurricane Maria made landfall in Puerto Rico, the effects continue to devastate the medical industry both on the island and the mainland. The power grid on the island remains mostly inoperable, leaving Puerto Rico’s many medical equipment manufacturing plants unable to operate. The United States Food and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Though it has been nearly four months since Hurricane Maria made landfall in Puerto Rico, the effects continue to devastate the medical industry both on the island and the mainland. The power grid on the island remains mostly inoperable, leaving Puerto Rico’s many medical equipment manufacturing plants unable to operate.

The United States Food and Drug Administration (FDA) has confirmed that the U.S. territory of Puerto Rico typically produces about $40 billion worth of pharmaceuticals each year. This amounts to more pharmaceutical production than any one of the 50 states, any other U.S. territory, or any single foreign country. Unfortunately, these productive manufacturing facilities have mostly shut down since Hurricane Maria hit land nearly four months ago, and the plants that are in operation continue to rely on generators.

Three of the affected manufacturing plants are home to Baxter, one of the most significant suppliers of IV bags. All three of Baxter’s plants on the island were forced to stall manufacturing. While two stations are now up and running on generators, the other remains closed.

According to the New York Times, about 10% of the drugs that Americans consume every day are made in Puerto Rico. While the island continues to recover from the devastating hurricane, medical professionals on the mainland should expect low supply, back orders, and price increases.

Unfortunately, these drug shortages could affect Accutome by Keeler and its customers. Ophthalmology offices should be aware of this backup and prepare accordingly. These professionals should expect Accutome and other providers to be out of certain products like morphine, IV solutions, mesh, surgical scalpels, and more. While the provider works hard to secure these products for customers.

The FDA is working with the manufacturers in Puerto Rico to get production back on track. The agency is currently monitoring a total of 90 products in hopes of stopping shortages before they become critical. The administration is also working with Puerto Rico to get manufacturing back on track.

“We continue to work closely with federal and Puerto Rican authorities to address the needs of manufacturers on the island for power and other resources. … Mitigating medical product shortages will require a sustained effort by the industry, the agency, and other partners as we work with manufacturers to return to production levels that adequately meet the needs of patients,” FDA Commissioner Scott Gottlieb, MD, said in a statement.

Thanks to generous tax incentives, Puerto Rico is home to many big-name manufacturers such as Johnson & Johnson, Pfizer, and Abbott Medical Optics. However, because only about half of these manufacturers are producing right now, medical professionals across the United States are destined to feel the shortage.

Since 2014, the FDA has been monitoring Puerto Rico for potential drug shortages. But Hurricane Maria turned a potential problem into a significant and immediate emergency. This shortage has made it difficult for cancer patients to receive proper care because Baxter makes the saline bags used for treatments. Furthermore, care of premature babies has been placed in jeopardy due to the shortage.

Accutome by Keeler is in its fourth decade of operation and will not allow this hurricane to end its reputation as a leader in the ophthalmic industry. With superior customer service, quality, and innovation, the company will continue to serve its customers through this crisis. Customers should feel free to contact their representatives with any questions they may have.

Accutome by Keeler stands with the people of Puerto Rico, its customers, and its commitment to service. While Hurricane Maria may have disrupted supplies, customers will not see a disruption in the service they have come to expect.

Read more at accutome.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris Life Sciences completed approximately 61,500 clinical cases in Q3 2026 and raised 2026 revenue guidance to $1.04-$1.05 billion. Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a minimal residual disease assay, is targeted to launch before year-end.

  • 01Caris said higher operating expenses were driven primarily by headcount-related costs, research and development investment and marketing.
  • 02Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a whole genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
  • 03Caris reaffirms its guidance for clinical therapy selection volume growth of approximately 20%.

Nov 8, 2026

Denials get a queue, underpayments just look like paid claims

Denials get a queue, underpayments just look like paid claims

Underpayments in healthcare revenue cycle operations lack the visibility of denied claims because they don't trigger alerts or queue workflows. Without dedicated ownership and line-level verification against contract terms, paid claims that fall short of their contractual amount pass through undetected.

  • 01Denial workflows activate on rejection events, but underpayments produce no event, leaving paid claims unverified by default.
  • 02The speaker says many provider groups lack line-level contract intelligence to check each paid line against the applicable terms.
  • 03Payment received and payment checked are separate tasks: one verifies acceptance, the other verifies correctness—and the second often has no assigned owner.

Nov 6, 2026

A zero-paid claim line is not automatically an underpayment

A zero-paid claim line is not automatically an underpayment

A zero payment on a claim line isn't automatically an underpayment; contract terms, particularly packaging rules, determine whether zero is correct. Chasing unsupported findings damages credibility with payers and weakens the position of legitimate disputes, so revenue cycle teams must verify the full contract terms and effective dates before treating any payment difference as a finding.

  • 01When a contract packages add-ons into the primary procedure, the add-on line may legitimately show zero payment because it is folded into the primary procedure reimbursement.
  • 02Pursuing payment differences that lack contract support burns credibility with payers and can weaken the team’s position on later disputes, including valid ones.
  • 03Always verify the complete contract terms, fee schedules, carve-outs, amendments, and the specific version in effect on the date of service before treating a payment variance as a recoverable underpayment.

Nov 6, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512